ICAM1 and systemic sclerosis: Moreover, therapy naïve SSc-ILD cases (n = 12/32) differed remarkably only in levels of ICAM1 + EVs compared to treated patients [50.8 (2.5–359.0) vs. 6.6 (0.6–71.3), p = 0.01].